ライフサイエンスコーパス: trough concentration

1 the first three cycles to evaluate valspodar trough concentration.

2 rve at steady-state and minimum steady-state trough concentration.

3 observed only in the presence of antibiotic trough concentrations.

4 ic outcomes it is recommended to monitor IFX trough concentrations.

5 erse event-related dose reductions at higher trough concentrations.

6 ts achieving predefined reduced cyclosporine trough concentrations.

7 n variants in the AA group towards the first trough concentrations.

8 L loading dose and a reduction in TAC target trough concentrations.

9 ugh concentration from first to second dose (trough concentration = 0.822 and 1.23 ng/mL for weeks 1

10 for weeks 1 and 2, respectively, with 24 mg; trough concentration = 0.993 and 1.47 ng/mL for weeks 1

11 morphism rs2244613 was associated with lower trough concentrations (15% decrease per allele; 95% conf

12 detectable HCV RNA (29% vs 25%) and mean RBV trough concentration (2.48 vs 2.14 mug/mL) were comparab

13 g intervals and observed wide variability in trough concentrations (6.7-fold for meropenem, 3.8-fold

14 0 mug/mL vs. 53.0 +/- 12.3 mug/mL) and lower trough concentrations (7.2 +/- 5.2 mug/mL vs. 12.3 +/- 5

15 the association between discharge tacrolimus trough concentration and the incidence of biopsy-proven

16 higher doses of tacrolimus to achieve target trough concentrations and are more likely to experience

17 se interferon alfa-2b and ribavirin peak and trough concentrations and area-under-the-curve were simi

18 ealed an independent association between VRC trough concentrations and probability of response or neu

19 We evaluated mean TAC C0 (tacrolimus trough concentration) and TAC time in therapeutic range

20 e polymorphism rs2244613 was associated with trough concentrations, and the ABCB1 single-nucleotide p

21 of intrapatient variability for cyclosporine trough concentrations as determined by %CV (P<0.05).

22 The mean+/-SD tacrolimus trough concentration at discharge (median postoperative

23 median (interquartile range) daily dose and trough concentration at time of nephrotoxicity were 400

24 using doses selected to maintain whole blood trough concentrations at therapeutic values between 40 a

25 eek after transplantation nor time to target trough concentration between patients later experiencing

26 Cyclosporine doses were adjusted to achieve trough concentrations between 100 and 300 ng/mL.

27 g/day, whichever dose was lower, to maintain trough concentrations between 5 and 15 ng/mL.

28 oncentration-time curves, and >/=36% for the trough concentration (C(0)).

29 ping patients into quartiles according to IM trough concentration (C(min)).

30 s, saquinavir area under the curve (AUC) and trough concentrations (C(min)), and virologic response.

31 ms with SRL dose-adjusted, weight-normalized trough concentrations (C/D) at 7 days, and at 1, 3, 6, a

32 nce, pretransplant laboratory values and SRL trough concentrations (C0) were correlated with the occu

33 study, and correlated with plasma ritonavir trough concentrations (C24).

34 cted a pharmacokinetic study to evaluate EFV trough concentrations (Cmin) and human immunodeficiency

35 Efavirenz trough concentrations (Cmin) were predicted using popula

36 (TAC) formulation and has a good exposure to trough concentration correlation.

37 Only 1 patient showed a trough concentration (Ctrough) below the suggested targe

38 n SC dose that would yield a rituximab serum trough concentration (Ctrough) in the same range as that

39 BV/PTV/r + DSV + darunavir (DRV) lowered DRV trough concentration (Ctrough) levels.

40 nt was the ratio of observed rituximab serum trough concentrations (Ctrough) between groups at cycle

41 ong randomized trials the mean of tacrolimus trough concentration during the first month was positive

42 one-third of patients, it was observed that trough concentrations exceeded the therapeutic window.

43 One-third of patients had an adalimumab trough concentration exceeding 7 mg/L.

44 domized trials directly comparing tacrolimus trough concentrations (five trials for acute rejection [

45 5 days and approximately 50% accumulation of trough concentration from first to second dose (trough c

46 leukopenia correlated significantly with SRL trough concentrations > or =16 ng/ml (P=0.001 and 0.0001

47 +/- 0.3 g/day and the individual median MPA trough concentration in the time period of anticipated c

48 The median tacrolimus trough concentration in week 1 posttransplant was partic

49 Similarly, median (IQR) time-averaged trough concentrations in breast milk were 3.3 ng/mL (2.3

50 ere is significant variability in antibiotic trough concentrations in critically ill patients receivi

51 creased proportionally up to 120 mg/day with trough concentrations in the in-vitro active range from

52 of dosage to maintain whole blood tacrolimus trough concentrations in the usual therapeutic range can

53 Trough concentrations increased less than proportionally

54 28.6%) of the 119 patients with a tacrolimus trough concentration less than 8 ng/mL and 19 (19.6%) of

55 on predisposed to BPAR, discharge tacrolimus trough concentration less than 8 ng/mL was associated wi

56 el-reactive antibody, a discharge tacrolimus trough concentration less than 8 ng/mL was significantly

57 en occurred among patients who displayed SRL trough concentrations < or =9 ng/ml.

58 [n = 712]) showed that "reduced tacrolimus" trough concentrations (<10 ng/mL) within the first month

59 emic exposure of tacrolimus, despite similar trough concentrations, may in the long run increase the

60 Daily doses used and trough concentrations measured were compared in 12 LDLT

61 The median (interquartile range) trough concentrations (mg/L) for meropenem was 12.1 (7.8

62 Using CLSI and EUCAST methodologies, the trough concentration:MIC values that achieved suppressio

63 Although non-trough concentrations might have underestimated the freq

64 olimus clearance (daily tacrolimus dose [mg]/trough concentration [mug/L]) and biopsy-proven acute re

65 The alisertib steady-state trough concentration (n = 25) revealed the expected phar

66 Interestingly, the trough concentrations obtained from the bell-shaped curv

67 ice daily with dose adjustment to maintain a trough concentration of 100 to 125 ng/mL.

68 rs than 3435CC homozygotes at an average SRL trough concentration of 4 ng/mL without concomitant medi

69 are meter of body-surface area, to achieve a trough concentration of 5 to 15 ng per milliliter.

70 +/- 57 mug/mL, which exceeded the effective trough concentration of 60 mug/mL observed in xenograft

71 o two groups based on a discharge tacrolimus trough concentration of 8 ng/mL.

72 Median estimated trough concentration of trastuzumab at the end of 3 week

73 cipients randomized to everolimus, targeting trough concentrations of 3-8 or 6-12 ng/mL plus reduced-

74 5 mg/m(2) per day (titrated to achieve blood trough concentrations of 5-15 ng/mL) or placebo.

75 sted subject to tolerability to attain blood trough concentrations of 5-15 ng/mL.

76 With mean trough concentrations of 7 ng/ml and higher, grafts surv

77 apy might not be a direct function of plasma trough concentrations of C1 inhibitor.

78 Trough concentrations of everolimus and octreotide were

79 l serum, breast milk, and infant serum daily trough concentrations of lithium averaged 0.76, 0.35, an

80 The mean steady state peak and trough concentrations of rituximab were 461 mug/mL (SD 9

81 raction, namely increases in the whole blood trough concentrations of SRL ([SRL(WB)]) and CsA ([CsA(W

82 Lower trough concentrations of tacrolimus (6-10 ng/mL during t

83 We hypothesized that current trough concentrations of tacrolimus after liver transpla

84 concentration, AUC(0-12 hours), and predose trough concentrations of tipifarnib.

85 The trough concentrations of valspodar were > or = 1,000 ng/

86 rted medication adherence scale and IS blood trough concentrations over 6 months, in four transplant

87 lected in the standard monitoring parameter, trough concentrations (P=0.80).

88 pregnancy make interpretation of whole blood trough concentrations particularly challenging.

89 reached during cycle 3 with mean maximum and trough concentrations ranging from 419 mug/mL (geometric

90 Trough concentrations remained consistent throughout the

91 tles inoculated with the peak, midpoint, and trough concentrations, respectively (P </= 0.001).

92 ntinuation, conversion to reduced TAC target trough concentrations resulted in significantly improved

93 Mean trough concentration (+/- standard deviation) at 9 mg/kg

94 Everolimus trough concentrations targeted to 3-8 ng/mL, along with

95 reduced using an algorithm to reach a target trough concentration (TC) of 3-7 mug/mL in all patients

96 l studies) to determine how lower tacrolimus trough concentrations than currently recommended affect

97 ntration-dependent activity, and resulted in trough concentration that would minimize the risk of myo

98 e were no significant differences in neither trough concentrations the first week after transplantati

99 imed to assess the variability of antibiotic trough concentrations, the influence of effluent flow ra

100 nous fluconazole appear to increase oral CNI trough concentrations to a similar extent even after adj

101 Mean plasma trough concentration was 0.57 microg/mL (approximately 1

102 Despite the lower doses used, mean trough concentration was significantly greater in LDLT a

103 wild-type virus, the efficacy of the PIs at trough concentrations was unaffected by a 4-fold increas

104 es were 4.4 and 4.5 mg/d and mean tacrolimus trough concentrations were 5.8 and 5.9 ng/mL before and

105 es were 4.6 and 4.6 mg/d and mean tacrolimus trough concentrations were 6.1 and 5.9 ng/mL before and

106 Adequate trough concentrations were achieved in all patients with

107 treatment, FTY720 effective doses and 24 hr trough concentrations were at least tenfold lower in com

108 Steady-state trough concentrations were reached by day 15 and did not

109 Tacrolimus doses and trough concentrations were similar between treatment gro

110 rican Americans (n=684), but mean tacrolimus trough concentrations were similar.

111 t month 1 or in area under the curve0-4h and trough concentration when measured at months 3 and 6.

112 and positive association of the fluconazole trough concentration with the fluconazole dose (P <.001)

113 119 mg/L, which is higher than steady-state trough concentrations with a conventional weekly or ever

114 The median proportion of tacrolimus trough concentrations within the target range was compar